CY1111538T1 - Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου - Google Patents
Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινουInfo
- Publication number
- CY1111538T1 CY1111538T1 CY20101100826T CY101100826T CY1111538T1 CY 1111538 T1 CY1111538 T1 CY 1111538T1 CY 20101100826 T CY20101100826 T CY 20101100826T CY 101100826 T CY101100826 T CY 101100826T CY 1111538 T1 CY1111538 T1 CY 1111538T1
- Authority
- CY
- Cyprus
- Prior art keywords
- phosphoramid
- compounds
- nucleozitic
- producers
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- -1 nucleoside compounds Chemical class 0.000 abstract 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229960002436 cladribine Drugs 0.000 abstract 1
- 229960000928 clofarabine Drugs 0.000 abstract 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 abstract 1
- 125000004437 phosphorous atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505781.5A GB0505781D0 (en) | 2005-03-21 | 2005-03-21 | Chemical compounds |
| EP06710096A EP1866324B1 (en) | 2005-03-21 | 2006-03-16 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111538T1 true CY1111538T1 (el) | 2015-08-05 |
Family
ID=34531603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100826T CY1111538T1 (el) | 2005-03-21 | 2010-09-10 | Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8263575B2 (enExample) |
| EP (1) | EP1866324B1 (enExample) |
| JP (2) | JP5345381B2 (enExample) |
| CN (2) | CN103936807A (enExample) |
| AT (1) | ATE471334T1 (enExample) |
| AU (1) | AU2006226182C1 (enExample) |
| BR (1) | BRPI0609704B8 (enExample) |
| CA (1) | CA2602324C (enExample) |
| CY (1) | CY1111538T1 (enExample) |
| DE (1) | DE602006014949D1 (enExample) |
| DK (1) | DK1866324T3 (enExample) |
| ES (1) | ES2348741T3 (enExample) |
| GB (1) | GB0505781D0 (enExample) |
| IL (1) | IL186104A (enExample) |
| MX (1) | MX2007011666A (enExample) |
| PL (1) | PL1866324T3 (enExample) |
| PT (1) | PT1866324E (enExample) |
| SI (1) | SI1866324T1 (enExample) |
| WO (1) | WO2006100439A1 (enExample) |
| ZA (1) | ZA200709011B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| AU2012216500B2 (en) * | 2006-11-24 | 2013-06-20 | Katholieke Universiteit Leuven | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| BRPI1004575A2 (pt) | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
| EA026341B9 (ru) | 2010-03-31 | 2021-12-27 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Кристаллическая форма нуклеозидфосфорамидата |
| GB201016855D0 (en) * | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| WO2012092484A2 (en) * | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| CA2828326C (en) | 2011-03-01 | 2019-05-07 | Nucana Biomed Limited | Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer |
| WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
| EP3235824B1 (en) | 2012-11-16 | 2019-03-27 | University College Cardiff Consultants Limited | Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| AU2014354775A1 (en) | 2013-11-27 | 2016-05-19 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
| RU2016149761A (ru) * | 2014-05-28 | 2018-07-02 | АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Производные нуклеозидов для лечения ракового заболевания |
| WO2015181624A2 (en) * | 2014-05-28 | 2015-12-03 | Idenix Pharmaceuticals, Inc | Nucleoside derivatives for the treatment of cancer |
| HRP20191461T1 (hr) | 2014-11-28 | 2019-11-15 | NuCana plc | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| BR112018009946A8 (pt) * | 2015-11-16 | 2019-02-26 | Ichorion Therapeutics Inc | pró-fármacos de ácido nucleico |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609602D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| WO2018071675A1 (en) * | 2016-10-12 | 2018-04-19 | Georgetown University | Cd99 inhibitors and their uses |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880000094B1 (ko) * | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
| CA2004695C (en) * | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
| DE4418690A1 (de) * | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| DK0821692T3 (da) | 1995-04-21 | 2006-05-22 | Univ South Florida | Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf |
| JP3761958B2 (ja) * | 1996-03-12 | 2006-03-29 | 彰 松田 | ３′−カルバモイルアルキルヌクレオシド誘導体 |
| US6245750B1 (en) * | 1998-01-23 | 2001-06-12 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
| GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| JP4768909B2 (ja) * | 2000-09-29 | 2011-09-07 | 扶桑薬品工業株式会社 | トポイソメラーゼ阻害剤 |
| US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
| KR20050059975A (ko) * | 2001-06-22 | 2005-06-21 | 파마셋 인코포레이티드 | β-2'- 또는 3'-할로뉴클레오시드 |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| US20070265222A1 (en) * | 2004-06-24 | 2007-11-15 | Maccoss Malcolm | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection |
| CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
-
2005
- 2005-03-21 GB GBGB0505781.5A patent/GB0505781D0/en not_active Ceased
-
2006
- 2006-03-16 PT PT06710096T patent/PT1866324E/pt unknown
- 2006-03-16 JP JP2008502453A patent/JP5345381B2/ja not_active Expired - Fee Related
- 2006-03-16 SI SI200630762T patent/SI1866324T1/sl unknown
- 2006-03-16 DE DE602006014949T patent/DE602006014949D1/de active Active
- 2006-03-16 ES ES06710096T patent/ES2348741T3/es active Active
- 2006-03-16 CN CN201410186829.5A patent/CN103936807A/zh active Pending
- 2006-03-16 US US11/886,931 patent/US8263575B2/en not_active Expired - Fee Related
- 2006-03-16 ZA ZA200709011A patent/ZA200709011B/xx unknown
- 2006-03-16 AT AT06710096T patent/ATE471334T1/de active
- 2006-03-16 PL PL06710096T patent/PL1866324T3/pl unknown
- 2006-03-16 BR BRPI0609704A patent/BRPI0609704B8/pt not_active IP Right Cessation
- 2006-03-16 AU AU2006226182A patent/AU2006226182C1/en not_active Ceased
- 2006-03-16 CA CA2602324A patent/CA2602324C/en active Active
- 2006-03-16 EP EP06710096A patent/EP1866324B1/en active Active
- 2006-03-16 WO PCT/GB2006/000932 patent/WO2006100439A1/en not_active Ceased
- 2006-03-16 CN CNA200680016708XA patent/CN101175763A/zh active Pending
- 2006-03-16 MX MX2007011666A patent/MX2007011666A/es active IP Right Grant
- 2006-03-16 DK DK06710096.6T patent/DK1866324T3/da active
-
2007
- 2007-09-20 IL IL186104A patent/IL186104A/en active IP Right Grant
-
2010
- 2010-09-10 CY CY20101100826T patent/CY1111538T1/el unknown
-
2013
- 2013-05-07 JP JP2013097919A patent/JP5863702B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2602324A1 (en) | 2006-09-28 |
| AU2006226182A1 (en) | 2006-09-28 |
| BRPI0609704B1 (pt) | 2020-12-01 |
| AU2006226182B2 (en) | 2011-09-01 |
| US20090215715A1 (en) | 2009-08-27 |
| JP2008533191A (ja) | 2008-08-21 |
| PT1866324E (pt) | 2010-09-16 |
| IL186104A0 (en) | 2008-01-20 |
| DE602006014949D1 (de) | 2010-07-29 |
| BRPI0609704A2 (pt) | 2010-04-20 |
| IL186104A (en) | 2013-06-27 |
| SI1866324T1 (sl) | 2010-10-29 |
| JP2013173786A (ja) | 2013-09-05 |
| JP5863702B2 (ja) | 2016-02-17 |
| CN101175763A (zh) | 2008-05-07 |
| ES2348741T3 (es) | 2010-12-13 |
| ATE471334T1 (de) | 2010-07-15 |
| DK1866324T3 (da) | 2010-09-27 |
| AU2006226182C1 (en) | 2012-06-14 |
| GB0505781D0 (en) | 2005-04-27 |
| JP5345381B2 (ja) | 2013-11-20 |
| WO2006100439A1 (en) | 2006-09-28 |
| CA2602324C (en) | 2015-02-24 |
| US8263575B2 (en) | 2012-09-11 |
| PL1866324T3 (pl) | 2010-12-31 |
| EP1866324B1 (en) | 2010-06-16 |
| BRPI0609704B8 (pt) | 2021-09-28 |
| CN103936807A (zh) | 2014-07-23 |
| MX2007011666A (es) | 2007-11-14 |
| EP1866324A1 (en) | 2007-12-19 |
| ZA200709011B (en) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111538T1 (el) | Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου | |
| CY1125603T1 (el) | Χημικες ενωσεις | |
| CY1113647T1 (el) | Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια | |
| CY1125294T1 (el) | Μεθοδοι για την αγωγη μολυνσεων απο ιο arenaviridae | |
| CY1124489T1 (el) | Αναστολεις της hpk1 και μεθοδοι χρησης αυτων | |
| CY1108470T1 (el) | Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna | |
| CY1120995T1 (el) | Ετεροκυκλικη ενωση και χρηση αυτης | |
| CY1116156T1 (el) | Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο | |
| CY1116929T1 (el) | Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β | |
| CY1118526T1 (el) | Παραγωγα διϋδροπυραζολοπυριμιδινονης | |
| CY1118472T1 (el) | Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων | |
| CY1118612T1 (el) | Μεθοδοι και χημικες συνθεσεις για την θεραπευτικη αντιμετωπιση των εμμενουσων λοιμωξεων και του καρκινου μεσω αναστολης της οδου προγραμματισμενου κυτταρικου θανατου 1 (pd-1) | |
| CY1111507T1 (el) | Ακυκλικοι αμινικοι αναστολεις των νουκλεοζιτικων φωσφορυλασων και υδρολασων | |
| CY1108254T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
| CY1118602T1 (el) | Αντινεοπλασματικοι συνδυασμοι 4-ανιλινο-3-κυανοκινολινων και καπεσιταβινης | |
| EA201892745A1 (ru) | Фосфорамидатные производные нуклеозида в качестве противораковых агентов | |
| CY1115239T1 (el) | Αντιμικροβιακες ενωσεις | |
| CY1122835T1 (el) | Συνδυαστικη θεραπεια | |
| CY1112570T1 (el) | Θεραπεια καρκινων με μετασταση | |
| ATE443717T1 (de) | Metastin derivate und ihre verwendung | |
| GT200200190A (es) | Compuestos de benzimidazol sustituido y su utilizacion en el tratamiento del cancer | |
| CY1109187T1 (el) | Νεα μακρολιδια | |
| WO2008087558A3 (en) | Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use | |
| PA8466101A1 (es) | Agentes terapeuticos | |
| CY1120203T1 (el) | Μεθοδοι θεραπειας αιματολογικου καρκινου με τη χρηση αναστολεα ρνρ, οπως φοροδεσινη σε συνδυασμο me anti-cd20 παραγοντα |